Wire · opportunities
Adicet Bio CAR-T sparks lupus remissions in early-stage trial
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 September 2026 · Fusion42 review
Adicet Bio's off-the-shelf CAR-T cell therapy prula-cel achieved remission in over half of lupus patients in a phase 1 trial without serious side effects seen in other CAR-T autoimmune trials, indicating a potential new treatment era. The FDA has approved a single-arm pivotal trial for lupus nephritis starting next year.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You need to rethink autoimmune treatment approaches as off-the-shelf CAR-T therapies like Adicet’s prula-cel show safer and effective immune resets that could replace lifelong immunosuppressants. This trial opens a door to single-dose cell therapy breakthroughs in diseases previously stuck on complex drug combinations.
◆ Coverage
1 source · 28 Sep 2026
◆ Related on Wire
◆ Topics